← Eichor
Study identifier: NCT07197554 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Condition: Advanced Solid Tumors · Ewing Sarcoma · Hepatocellular Carcinoma (HCC)  ·  Sponsor: SEED Therapeutics, Inc.

PhasePhase 1
Planned participants171
Who can joinAll sexes, 16 Years to no upper limit
Healthy volunteersNo

About this study

A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

This description comes directly from the study's public registry record.

Talk to the study team

Dr. Eric Rowinsky Chief Medical Officer  ·  (908) 883-0647  ·  erowinsky@oncodrugs.com

Always discuss trial participation with your own doctor first.

Locations (6)

The City of Hope National Medical CenterDuarte, California, United StatesRecruiting
Hoag Memorial HospitalNewport Beach, California, United StatesRecruiting
Mass General Brigham Cancer InstituteBoston, Massachusetts, United StatesRecruiting
Dana Farber Cancer InstituteBoston, Massachusetts, United StatesRecruiting
Memorial Sloan Kettering Cancer CenterNew York, New York, United StatesRecruiting
The University of Texas MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07197554